Russian drugmaker Binnopharm Group has announced an expansion of its women’s health product portfolio, according to a statement from the company provided to GxP News. The company has launched three new products: the contraceptive Dezeria (desogestrel), Didromens (dydrogesterone) for conditions related to progesterone deficiency, and Ginocare, an external-use antiviral spray containing ammonium glycyrrhizinate.
Furthermore, Normetrilla (dienogest), a drug for endometriosis treatment launched in June, has captured a significant 8.5% market share in terms of packages within just a few months. The company’s press service stated that over 11,200 packages of the drug have been sold to date.
“We are not only enhancing our portfolio with modern drugs but also guaranteeing their accessibility through our own manufacturing expertise and optimized supply chains,” said Ekaterina Slavgorodskaya, Director of the Sales and Promotion Department at Binnopharm Group.
According to the State Register of Medicines (GRLS), drugs with these active ingredients are already available on the Russian market. For instance, the desogestrel tablet market includes the original product, Charozetta from the Dutch company Organon N.V., as well as PlaniGens Lacto from Pharmasintez-Tyumen, and a product from Macedonia’s Alkaloid.
The Russian Society of Obstetricians and Gynecologists has drawn up the country’s first-ever clinical guidelines on contraception. A document called “Contraception. Monitoring the Use of Contraceptives” was presented in September at a seminar on Russia’s reproductive potential. You can read more about the development in the GxP News article.